Related Experiment Video
Updated: Apr 4, 2026
Detrusor Underactivity Model in Rats by Conus Medullaris Transection
Published on: August 28, 2020
Emerging drugs for overactive bladder
Roopali Karmarkar1, Vik Khullar2
1a 1 Clinical Research Fellow, St Mary's Hospital, Imperial College, Urogynaecology Department , London, UK +44 0 79 83 41 40 71 ; roopalikarmarkar@gmail.com.
Introduction:
Overactive bladder (OAB) is a common problem which can have disastrous effects on the quality of life of the sufferer. There are established treatments for the problem but they have significant adverse effects. Better drugs and new treatment modalities are necessary to deal with OAB.
Area Covered:
Antimuscarinics, mirabegron and intravesical injection of botulinum toxin A are established treatments for OAB. Sacral neuromodulation is more invasive but has been successful in treating OAB. Phase II and III trials are in progress for newer β3-agonists and various combinations of antimuscarinics, β3-agonists and antidiuretics. Targeted secretion inhibitors (TSI) can increase efficacy and reduce adverse effects. Liposome integrated botulinum toxin A has an advantage of effective administration by intravesical instillation. Both medicines are in Phase II trials. Many other drugs which have promising results are discussed.
Expert Opinion:
Newer antimuscarinics have better tolerability. Long-term data for mirabegron has shown that it is more effective in severe OAB. Combination drugs may prove to be more effective with less adverse effects. Emerging treatments with TSI, lipotoxin and gene therapy appear promising.
Insights
Overactive bladder (OAB) treatments are evolving. Newer medications and therapies show promise for improved efficacy and reduced side effects in managing OAB symptoms.
Area of Science:
- Urology
- Pharmacology
- Medical Technology
Background:
- Overactive bladder (OAB) significantly impacts patient quality of life.
- Current OAB treatments have notable adverse effects, necessitating improved options.
Purpose of the Study:
- To review established and emerging treatments for overactive bladder (OAB).
- To discuss the efficacy and tolerability of novel therapeutic approaches for OAB.
Main Methods:
- Review of established treatments including antimuscarinics, mirabegron, and botulinum toxin A.
- Discussion of ongoing Phase II and III trials for novel β3-agonists, combination therapies, targeted secretion inhibitors (TSI), and liposome-integrated botulinum toxin A.
- Exploration of emerging treatments like gene therapy.
Main Results:
- Newer antimuscarinics demonstrate improved tolerability.
- Mirabegron shows enhanced effectiveness in severe OAB cases based on long-term data.
- Combination therapies may offer superior efficacy with fewer adverse effects.
Conclusions:
- Emerging treatments such as targeted secretion inhibitors (TSI), lipotoxin, and gene therapy present promising avenues for OAB management.
- Advancements in OAB pharmacotherapy and treatment modalities are crucial for better patient outcomes.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
01:23Urinary Bladder
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists